<a href="https://laohu8.com/S/IGC">IGC Pharma</a> Reports Lower Revenue Amid Shift to Alzheimer's Drug Development
IGC Pharma Inc. reported revenue of approximately $191.0 thousand for the three months ended September 30, 2025, down from $412.0 thousand in the same period in 2024. The decrease in revenue was primarily due to the company's focus on advancing IGC-AD1, completing the Phase 2 clinical trial, and developing MINT-AD for early diagnosis of Alzheimer's disease, as well as a planned transition period linked to the disposition of its Vancouver manufacturing facility. Cost of revenue for the six months ended September 30, 2025, was about $266.0 thousand compared to $323.0 thousand in the prior year. The company reported a net loss of $1.8 million for the quarter, compared to a net loss of $1.7 million in the same period in 2024. During the quarter, IGC Pharma reached over 50% enrollment in its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation in Alzheimer's disease.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001185185-25-001752), on November 14, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。